SCHEMBL6715254

SCHEMBL6715254

COc1ccc(-c2ccc(C(=O)NCCOc3ccc(CC(C)(Oc4ccc(C(C)C)cc4)C(=O)O)cc3)cn2)cc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 4/20 0.46
NPC1 O15118 3/20 0.46
RAB9A P51151 2/20 0.46
ALDH1A1 P00352 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
GCG P01275 1/20 0.43
RXFP1 Q9HBX9 1/20 0.41
TRPV1 Q8NER1 1/20 0.41
PPARA Q07869 6/20 0.41
PPARG P37231 5/20 0.41
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
PPARD Q03181 4/20 0.40
POLB P06746 1/20 0.39
CASP3 P42574 1/20 0.39
SENP7 Q9BQF6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6715219 0.91 HCAR2 (0.46) HCAR2NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL6713501 0.86 NPC1 (0.46) HCAR2NPC1RAB9ASMN1; SMN2PPARA
SCHEMBL6715966 0.83 GCG (0.49) HCAR2NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL6712975 0.81 GCG (0.47) HCAR2NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL6713371 0.80 EPHX2 (0.45) NPC1RAB9AALDH1A1SMN1; SMN2MEN1
SCHEMBL6715831 0.78 NPC1 (0.53) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL6715146 0.78 GCG (0.53) HCAR2NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL6716238 0.77 MAPT (0.48) HCAR2NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL6713526 0.77 PPARA (0.42) HCAR2NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL6715209 0.76 GCG (0.51) HCAR2NPC1RAB9AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6528525-B1 Amidocarboxylic acid derivatives SANKYO COMPANY, LIMITED (JP) 2003-03-04 US claimed
EP-1026149-A1 AMIDOCARBOXYLIC ACID DERIVATIVES Sankyo Company Limited (JP) 2000-08-09 EP claimed
US-20040006141-A1 Amidocarboxylic acid compounds SANKYO COMPANY, LTD (JP) 2004-01-08 US disclosed
US-6528525-B1 Amidocarboxylic acid derivatives SANKYO COMPANY, LIMITED (JP) 2003-03-04 US disclosed
EP-1026149-A1 AMIDOCARBOXYLIC ACID DERIVATIVES Sankyo Company Limited (JP) 2000-08-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006141-A1 Amidocarboxylic acid compounds NR1H2, AGK, APOL1 HCAR2 429/4885NPC1 812/4885RAB9A 3140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.